{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021914","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.956137+00:00","generated_at":"2026-05-16T20:55:59.364364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dyadic International Reports Q3 2025 Financial Results and Strategic Progress","bullets":["Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.","Net loss for Q3 2025 increased to $1.976 million from $0.203 million a year ago.","Completed strategic pivot to commercial focus; rebranded as Dyadic Applied BioSolutions.","Secured ERS Genomics CRISPR license to optimize protein production.","Received $1.5 million in milestone payments from Proliant for animal-free serum albumin."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021914","json":"https://secwatch.observer/filing/0001493152-25-021914.json","markdown":"https://secwatch.observer/filing/0001493152-25-021914.md","text":"https://secwatch.observer/filing/0001493152-25-021914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/0001493152-25-021914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T20:55:59.364364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}